The feasibility of patches was demonstrated in an acute MI model in mice for up to 14 days, in which the IGF-1/SP patch-treated group showed improved neovascularization, higher numbers of capillaries, augmented LV wall thickness, higher cardiac function, and reduced adverse cardiac remodeling than that of the saline, patch-only, or individual SP and IGF-1C peptide containing patches. This evidence concerns the gene IGF1 and myocardial infarction.